There is no cure for Leigh disease, and no single drug can halt or reverse it. The primary treatment is a combination of supportive care and targeted nutritional supplements, often called a “mitochondrial cocktail,” designed to improve how the body’s cells produce energy. Because Leigh disease stems from defects in mitochondrial energy production, treatment focuses on optimizing whatever cellular energy capacity remains, managing symptoms as they arise, and preventing metabolic crises that can cause rapid decline.
The Mitochondrial Cocktail
The cornerstone of Leigh disease treatment is a daily regimen of vitamins, antioxidants, and cofactors that support mitochondrial function. This is not a standardized prescription but a customized mix tailored to the specific genetic mutation and symptoms involved. The core components typically include coenzyme Q10 (ubiquinol), a B-vitamin complex, and an antioxidant such as vitamin E or alpha-lipoic acid.
Coenzyme Q10 plays a direct role in the electron transport chain, the energy-producing machinery inside mitochondria. Pediatric doses generally range from 2 to 8 mg per kilogram of body weight per day, while adults may take 50 to 600 mg daily, with a maximum of 1,200 mg. Riboflavin (vitamin B2) is another common addition, dosed between 50 and 400 mg per day, because it helps certain enzyme complexes in the mitochondria function more efficiently.
L-carnitine was once a standard part of the cocktail, used to help shuttle fatty acids into mitochondria and clear toxic byproducts. It is no longer routinely recommended due to concerns linking chronic use to cardiovascular risks. Your child’s specialist may still consider it in specific situations, but it has largely fallen out of standard protocols.
Treatments That Target Specific Mutations
Leigh disease is not one condition but a syndrome caused by more than 75 different genetic mutations. In a small number of cases, the specific mutation responds dramatically to a targeted vitamin therapy. The most notable example involves mutations in the SLC19A3 gene, which disrupts how the brain transports thiamine (vitamin B1). Children with this form of Leigh disease can improve significantly, and sometimes recover substantially, when treated with high-dose biotin (5 to 10 mg per kilogram per day) and thiamine (300 to 900 mg per day). During an acute crisis, these doses may be doubled and given intravenously.
This is why genetic testing matters so much in Leigh disease. Identifying the exact mutation can reveal whether a child has one of these treatable subtypes. Without that information, a potentially life-changing therapy might be missed.
Dietary Interventions
For children whose Leigh syndrome is caused by pyruvate dehydrogenase complex deficiency, a ketogenic diet is considered the gold-standard therapy. This high-fat, very-low-carbohydrate diet forces the body to burn fat for fuel instead of glucose, effectively bypassing the broken enzyme. The ketogenic diet has been shown to increase lifespan in these patients, reduce seizures, improve coordination problems, lower lactic acid levels, and even improve sleep. It works best in children whose symptoms appeared after the newborn period, who had higher developmental function before treatment, and who do not have structural brain abnormalities.
A ketogenic diet for Leigh disease requires close medical supervision. It is not appropriate for all genetic subtypes, and in some cases involving fatty acid oxidation defects, it can be harmful.
Managing Metabolic Crises
Children with Leigh disease are vulnerable to sudden metabolic crises, often triggered by illness, fever, fasting, or surgery. During these episodes, lactic acid builds up in the bloodstream, causing a dangerous condition called lactic acidosis. Treatment during a crisis typically involves sodium citrate or sodium bicarbonate to neutralize excess acid, along with intravenous fluids and careful calorie support to prevent the body from breaking down its own muscle for energy.
Families are generally taught to recognize early warning signs of a crisis, such as increased lethargy, vomiting, or rapid breathing, and to seek emergency care quickly. Preventing crises through careful management of fevers and infections is a central part of long-term care.
Symptom Management
As Leigh disease progresses, it produces a range of neurological symptoms that each require their own treatment approach. Seizures are common and managed with anti-seizure medications, though the choice of drug requires care because some can worsen mitochondrial function. Dystonia, the involuntary muscle contractions that cause twisting postures, is one of the most challenging symptoms to treat. Children who develop dystonia are typically first tried on levodopa, a medication that boosts a brain chemical involved in movement control. If that doesn’t help, other options include anticholinergic medications, baclofen (a muscle relaxant), or benzodiazepines like clonazepam. The approach is always individualized based on the child’s response and side effects.
Spasticity, or persistent muscle tightness, is managed with physical therapy and sometimes baclofen. Both dystonia and spasticity medications need to be tapered slowly rather than stopped suddenly, because abrupt withdrawal can trigger seizures.
Nutritional Support and Feeding
Many children with Leigh disease develop swallowing difficulties as the disease affects brainstem function. This creates two problems: they cannot take in enough calories to maintain weight, and food or liquid can enter the lungs, causing aspiration pneumonia. In a study of pediatric mitochondrial disease patients who needed feeding support, 59% had aspiration as an indication.
When swallowing problems persist beyond a few months, a gastrostomy tube (G-tube) placed directly into the stomach is the standard approach. About 82% of children with mitochondrial disease who need tube feeding receive a gastrostomy rather than a nasal tube, because the nasal route is only practical for short-term use of one to three months. A G-tube ensures reliable nutrition delivery and significantly reduces the risk of aspiration-related lung infections, which are a leading cause of hospitalization and decline in Leigh disease.
Monitoring Disease Progression
Children with Leigh disease are typically seen by their metabolic or neurological specialist one to two times per year for comprehensive evaluations. These visits usually include brain MRI scans to track the characteristic lesions in the brainstem and basal ganglia that define the disease, along with cardiac evaluations since some forms of Leigh disease affect the heart muscle. Blood and urine tests to measure lactic acid levels and other metabolic markers help gauge how well the mitochondrial cocktail and other interventions are working.
Gene Therapy on the Horizon
While no gene therapy is available for Leigh disease today, preclinical work has shown striking results. Researchers at Oxford used a viral vector to deliver a working copy of the NDUFS4 gene (one of the most common mutations behind Leigh syndrome) into the brains of mice that completely lacked the gene. Untreated mice typically die by around 50 days. Mice that received both an intravenous and a brain injection of the gene therapy at birth survived 6 to 9 months in healthy condition, with restored energy-producing enzyme activity and normal brain structure. Similar approaches have been tested for SURF1 mutations. These results remain in the animal research phase, but they represent the most promising path toward a treatment that addresses the root cause rather than managing symptoms.